Topiramate Capsule, Extended Release
Product Images NDC 42291-958

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Topiramate (NDC 42291-958). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Avkare, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

30 (955 30)

Topiramate Extended-release Capsules 25 mg label by AvKARE. The label includes dosage instructions to swallow whole and intact without opening or crushing. It specifies the package contains 30 capsules and is for oral use. The label displays the NDC 42291-955-30 and includes storage and precautionary information along with a QR code and barcode.*

FDA Label Image

30 (956 30)

Topiramate Extended-release Capsules 50 mg labeling for a 30-capsule package by AvKARE. The label includes dosage strength, administration instructions to swallow whole, and storage conditions. It features the AvKARE logo, NDC number 42291-956-30, and indicates the product is for oral use and prescription only.*

FDA Label Image

30 (957 30)

The image shows a label for Topiramate Extended-Release Capsules, 100 mg strength, by AvKARE. It is an oral prescription drug with 30 capsules per bottle. The label includes usage instructions, storage conditions, a barcode, and a QR code. The capsules should be swallowed whole and kept out of reach of children.*

FDA Label Image

30 (958 30)

Topiramate Extended-release Capsules 200 mg by AvKARE. The label indicates swallow capsule whole without opening or crushing. The package contains 30 capsules. It includes storage instructions and a caution to keep the medication out of reach of children.*

FDA Label Image

Structural Formula (Topiramate Extended Release Capsules A206210 1)

Chemical structure of Topiramate, depicting its molecular framework including multiple oxygen atoms, sulfonamide group, and methyl substitutions as illustrated in the diagram.*

FDA Label Image

1 (Topiramate Extended Release Capsules A206210 2)

A Kaplan-Meier curve chart showing cumulative rates for time to first seizure over 500 days. The graph compares Topiramate 50 mg/day and 400 mg/day dosage groups, with the 50 mg/day group showing higher cumulative seizure rates. The x-axis represents time in days, and the y-axis shows cumulative rates for time to first seizure.*

FDA Label Image

2 (Topiramate Extended Release Capsules A206210 3)

A bar graph comparing the change from baseline to double-blind day 105 in average weekly seizure frequency across placebo and topiramate doses (50 mg/day, 100 mg/day, 200 mg/day) for two studies. The graph shows greater seizure frequency reduction with increasing topiramate doses compared to placebo, with statistical significance indicated at various dose levels.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.